ArticleThe Kaohsiung journal of medical sciences2022
Morinda officinalis polysaccharide regulates rat bone mesenchymal stem cell osteogenic-adipogenic differentiation in osteoporosis by upregulating miR-21 and activating the PI3K/AKT pathway.
Article in The Kaohsiung journal of medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Morinda officinalis polysaccharide improves osteoporosis by enhancing m⁶A-modified SOCS5 mRNA stability via regulating the hsa_circ_0001165/IGF2BP2 axis.Molecular genetics and genomics : MGG · 2026Article
- Therapeutic potential of natural products from Traditional Chinese Medicine in the treatment of osteoporosis.Frontiers in pharmacology · 2026Review
- Mechanism of the enterobacterial metabolite sodium butyrate mediating ferroptosis to affect osteogenic ability of BMSCs in mice with estrogen deficiency-caused osteoporosis via the PTEN/PI3K/AKT pathway.Apoptosis : an international journal on programmed cell death · 2025Article
- Alleviating the IL-1β-stimulated extracellular matrix degradation in osteoarthritis, and chondrocyte inflammation byBiomolecules & biomedicine · 2025Article
- Article
- Morinda Officinalis Polysaccharides Inhibit Osteoclast Differentiation by Regulating miR-214-3p/NEDD4L in Postmenopausal Osteoporosis Mice.Calcified tissue international · 2024Article
- How mesenchymal stem cells transform into adipocytes: Overview of the current understanding of adipogenic differentiation.World journal of stem cells · 2024Review
- Therapeutic potential of Chinese medicinal herbs stimulating osteogenic differentiation of bone marrow-derived mesenchymal stem cells in osteoporosis.Frontiers in pharmacology · 2024Review
- The Role of Herbal Medicine in Modulating Bone Homeostasis.Current topics in medicinal chemistry · 2024Review
- Article
- Molecular mechanism of Achyranthis bidentatae radix and Morindae officinalis radix in osteoporosis therapy: An investigation based on network pharmacology, molecular docking, and molecular dynamics simulations.Biochemistry and biophysics reports · 2023Article
- Alternative Medical Therapy.Indian journal of orthopaedics · 2023Review
- The Potential of miR-21 in Stem Cell Differentiation and its Application in Tissue Engineering and Regenerative Medicine.Stem cell reviews and reports · 2023Review
- Optimization of Extraction Process, Preliminary Characterization and Safety Study of Crude Polysaccharides from Morindae Officinalis Radix.Foods (Basel, Switzerland) · 2023Article
- The Potential Therapeutic Effects of Platelet-Derived Biomaterials on Osteoporosis: A Comprehensive Review of Current Evidence.International journal of biomaterials · 2023Review
- Therapeutic approach of natural products that treat osteoporosis by targeting epigenetic modulation.Frontiers in genetics · 2023Review
- Morinda officinalis polysaccharide regulates rat bone mesenchymal stem cell osteogenic-adipogenic differentiation in osteoporosis by upregulating miR-21 and activating the PI3K/AKT pathway.The Kaohsiung journal of medical sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Osteoporosis (OP) is a prevailing bone metabolic disease. Morinda officinalis polysaccharide (MOP) has biological activities and medicinal potential. This study explored its mechanism in OP. Rat bone mesenchymal stem cells (rBMSCs) were pretreated with low/high concentrations of MOP and subjected to osteogenic differentiation (OD) or adipogenic differentiation (AD) induction. The protein markers of OD (RUNX2 and BMP2) and AD (CEBPα and PPARγ) and miR-21 expression were detected. miR-21 was overexpressed to study its effects on rBMSC OD and AD. rBMSCs were transfected with miR-21 inhibitor and treated with high concentration of MOP for verification. The targeted relationship between miR-21 and PTEN was verified by bioinformatics and dual-luciferase assay. The PTEN/PI3K/AKT pathway-related proteins were detected. Ovariectomy (OVX)-induced OP rats were treated with MOP. Rat bone mineral density (BMD), serum bone metabolism indexes bone-derived alkaline phosphatase (BALP), and osteocalcin (BGP) levels were assessed by BMD detectors and ELISA kits. miR-21 expression in rBMSCs was detected. After treatment with low/high concentrations of MOP, the OD of rBMSCs was increased and AD was inhibited and miR-21 was upregulated. miR-21 overexpression enhanced the OD of rBMSCs and inhibited AD. miR-21 knockdown reversed the effect of high concentration of MOP on rBMSCs. miR-21 targeted PTEN. After treatment with low/high concentrations of MOP, PI3K, and AKT phosphorylation were increased and the PI3K/AKT pathway was activated. BMD, BALP, BGP, and miR-21 levels in OVX rats were decreased. MOP partially alleviated OP in OVX rats. Briefly, MOP enhanced rBMSC OD and inhibited AD via the miR-21/PTEN/PI3K/AKT axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.